Shares of Danish diabetes giant Novo Nordisk (NVO) hit a new high early Thursday after the company beat Q4 estimates and raised its margin target. Net income in the quarter rose 23% over the prior year's quarter to 5.76 billion kroner, or $1.1 billion, beating the Bloomberg consensus estimate of 5.34 billion kroner. Sales rose 16% to 20.96 billion kroner, or $3.8 billion. The company said it's expecting sales growth of 8% to 11% this year, in line